To my knowledge MSB approval is in paediatric aGVHD so it’s a different indication to adult aGVHD. Further MSB focuses on steroid refractory Wheras the CYP trial is on high risk aGVHD. Lastly the CYP product may be more cost effective or have more efficacy even if both go to market. Anyway I’m sure if you ask an MSB person they’d give you a different answer!
CYP Price at posting:
22.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)